Orkambi FDA Approved Drugs
ORKAMBI [IvacaftorC24H28N2O3 : LumacaftorC24H18F2N2O5]
RX
- 125mg : 100mg (oral tablet)
125mg : 200mg (oral tablet)
Vertex Pharms IncSep 28, 2016
- Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor.
- Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using a dosage unit as defined in claim 1 of u.s. patent no. 9,192,606.
- Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and form i lumacaftor.
- Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and lumacaftor.
- Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using the dosage unit of claim 1 of u.s. patent no. 8,716,338.
- Method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
- Method of treating cystic fibrosis in patients who have the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene..
- Method of treating cystic fibrosis using n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide and 3-(6-(1-2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid.
- Method of treating cystic fibrosis.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.